{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":15},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07285239\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PrE1005","nct_id":"NCT07285239","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pre1005-nct07285239. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"PrE1005","arms":[{"description":"Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days.","label":"Arm A: Belantamab Mafodotin","type":"EXPERIMENTAL"},{"description":"Daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days.","label":"Arm B:","type":"ACTIVE_COMPARATOR"}],"collaborators":["GlaxoSmithKline"],"completion_date":{"date":"2034-06","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Arm A: Belantamab Mafodotin","type":"DRUG"},{"name":"Arm B: Daratumumab Hyaluronidase","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"}],"last_update":"2026-08-17","lead_sponsor":"PrECOG, LLC.","official_title":"Randomized Phase 3 Trial of Belantamab Mafodotin or Daratumumab in Combination With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"MRD Negative Status","timeFrame":"Up to 86 months"},{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 86 months"}],"references":[],"start_date":{"date":"2026-09","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT07285239"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pre1005-nct07285239"}